INTRODUCTION
Programmed cell death 4 (Pdcd4) was initially discovered during screening for genes activated during apoptosis and was subsequently found to be a tumor suppressor and an inhibitor of gene transcription and translation 1, 2 . It inhibits gene translation by binding to eukaryotic translation initiation factor (eIF)-4A or by binding directly to the target gene 3 and suppresses AP-1-dependent transcription by downregulating MAP4K1 4, 5 . Its expression is lost or reduced in several forms of human cancer, including lung cancer 6 , colorectal cancer 7 , and glioma 8 . Furthermore, Pdcd4 can suppress the malignant phenotype of tumors 9 and enhance their chemosensitivity 10 . Recent studies have suggested that Pdcd4 may also be involved in some inflammatory diseases. However, the role of Pdcd4 in inflammatory diseases demonstrates opposing effects (promotion or inhibition) in various disease models. Some researchers have shown that Pdcd4-deficient mice are resistant to autoimmune encephalomyelitis, LPS-induced shock, and type 1 diabetes [11] [12] [13] and that Pdcd4 deficiency prevents dietinduced obesity, adipose tissue inflammation, and insulin resistance 14 . Knockdown of Pdcd4 by specific siRNA suppressed allergic pulmonary inflammation, as demonstrated by attenuated airway eosinophil infiltration, bronchial collagen deposition, and mucus production 15 . These results imply that endogenous Pdcd4 promotes inflammation. However, our more recent research has shown that Pdcd4-deficient mice were more sensitive to LPS/D-galactosamine-induced acute liver injury. In this model, the Pdcd4-deficient mice had more necrotic and apoptotic hepatocytes, inflammatory cell infiltration, and liver internal hemorrhage, as well as increased aspartate . Atherosclerotic plaques are characterized by an accumulation of lipids within the intima of the artery, together with infiltration of immunocytes. Macrophages and T cells are the major components of this infiltrate, and the cytokines secreted by these cells play a critical role in the development of atherosclerosis 18 . Beneath the vascular intima, the macrophages phagocytize modified lowdensity lipoprotein (LDL) particles and become foam cells that produce many pro-inflammatory cytokines, including IL-6 and TNF-a that promote the formation of atherosclerotic plaques, as well as anti-inflammatory cytokines, including IL-10 and TGF-b, that inhibit the formation of plaques 19, 20 and initiate an adaptive immune response. Accumulating evidence indicates that CD4
1 T cells are the major type of T cells involved in atherosclerosis 21 . Reconstitution of immune-deficient scid/scid apolipoprotein E knockout (Apoe KO, Apoe
2/2
) mice with CD4
1 T cells accelerated atherosclerosis, whereas CD4-deficient C57BL/6 mice were protected against fatty streak formation 22, 23 , indicating that CD4 
CD4
1 ) cells promote the development of atherosclerosis primarily by releasing the cytokines IFN-c and IL-17 [24] [25] [26] . Although multiple cytokines are involved in atherosclerosis, IL-10 is one of the most important cytokines in this context 27 . Several studies have found that IL-10 has anti-inflammatory and antithrombotic potency 28, 29 . In the past few years, a series of studies have confirmed the role of endogenous IL-10 in animal models of atherosclerosis [30] [31] [32] . In Apoe and IL-10 double-KO mice, feeding a high fat diet was shown to enhance the formation of early atherosclerotic plaques compared with the Apoe single knockout mice 33 . Consistent with these observations, intramuscular gene transfer of IL-10 cDNA has been proven to reduce atherosclerotic plaques in Apoe . These results provided evidence that IL-10 is instrumental in preventing the development of atherosclerotic lesions. Therefore, molecules that can regulate the expression of IL-10 will affect atherosclerosis.
Previous studies have reported that Pdcd4 inhibits the expression of IL-10. Pdcd4 deficiency or knockdown upregulates expression of IL-10 in activated splenocytes and macrophages, and overexpression of Pdcd4 suppresses the expression of IL-10 in macrophages 11, 12, 35, 36 . More recent research has shown that Pdcd4 inhibits IL-10 expression by directly binding to Twist2 and then inhibiting Twist2-initiated c-Maf transcription 36 . These data suggest that Pdcd4 may affect the development of atherosclerosis by regulating the expression of IL-10.
In this study, we found that Pdcd4 deficiency in mice increased the expression of IL-10 in macrophages stimulated by oxidized LDL (oxLDL) in vitro and in high fat-induced atherosclerotic plaques. Importantly, knocking out Pdcd4 led to decreased atherosclerotic lesions in Apoe 2/2 mice fed with high fat diet, which could be partly reversed by blocking IL-10 with a neutralizing antibody. Furthermore, Pdcd4 negatively regulates the expression of IL-10 in an ERK1/2-and p38-dependent manner, suggesting that endogenous Pdcd4 promotes atherosclerosis partly by inhibiting the expression of IL-10.
MATERIALS AND METHODS

Mice
Apoe 2/2 mice on a C57BL/6 background and WT C57BL/6 mice were purchased from Beijing University (Beijing, China). The Pdcd4 2/2 mice on C57BL/6 background were generated as described previously 11 and were mated with the Apoe 2/2 mice to obtain the Pdcd4 2/2 Apoe 2/2 mice. All animal study protocols were approved by the Animal Care and Utilization Committee of Shandong University.
Induction of atherosclerosis
Sex-matched Pdcd4
1/1 Apoe 2/2 and Pdcd4 2/2 Apoe 2/2 mice were fed a high fat diet (0.25% cholesterol and 15% cocoa butter) from 8 weeks until 16 weeks of age to induce atherosclerotic lesions.
Histopathology, immunohistochemistry (IHC)
After the mice were sacrificed, the hearts with the attached aortic roots were removed and fixed in 4% paraformaldehyde overnight and then embedded in OCT compound at 220 uC. Serial frozen sections (6 mm thick) were cut along the aortic root for up to 200 mm until the valve leaflets were no longer detectable. Sections of the aortic root with aortic valve were stained with hematoxylin and eosin (H&E) to evaluate the amount of plaque. To detect the IL-17 expression in the plaques, corresponding sections on separate slides were incubated in 3% H 2 O 2 solution for 10 min at room temperature (RT) to block the endogenous peroxidase activity, incubated with rabbit anti-mouse IL-17 Ab (sc-7927, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at RT, and then with horseradish peroxidase (HRP) conjugated goat-anti-rabbit IgG (sc-2004, Santa Cruz Biotechnology) for 15 min at RT. After staining with DAB solution, the sections were treated with hematoxylin to stain the nuclei. The total areas of lesions and the positively stained regions were measured using Image Proplus 6.0 software, and the ratio of positively stained region to the total area of the lesion was calculated.
Immunofluorescence (IF)
To examine the expression of IL-17 in the CD4 1 T cells in the plaques, corresponding frozen sections on separate slides were analyzed by double IF staining with rabbit anti-mouse IL-17 Ab and FITC-conjugated goat-anti-rabbit IgG (sc-2012, Santa Cruz Biotechnology), and rat anti-mouse CD4 Ab (H129.19; BD Pharmingen, San Diego, CA, USA) and TRITC-conjugated goat-anti-rat IgG (3030-03, Southern Biotech, Birmingham, AL, USA). The expression of IL-10 in macrophages from plaques was detected by double IF staining with rat anti-mouse IL-10 Ab (ab33471, Abcam, Cambridge, UK) and TRITC-conjugated goat-anti-rat IgG, and rabbit anti-mouse CD68 Ab (sc-9139, Santa Cruz Biotechnology) and FITC-conjugated goat-anti-rabbit IgG, respectively. The cell nuclei were stained with Hoechst (94403, Sigma-Aldrich, Saint Louis, MO, USA). The different histological stains were examined using an Olympus microscope (IX71; Olympus Corporation, Tokyo, Japan).
Macrophages culture and treatment
Sex-matched Pdcd4
2/2 and C57BL/6 mice at 7-8 weeks old were intraperitoneally injected with 6% starch. After 3 days, the peritoneal macrophages were washed out and cultivated in 6-well flat bottom plates with Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and incubated in humidified 5% CO 2 at 37 uC for 2 h to allow macrophage adherence. Non-adherent cells were removed by three washes with DMEM. The adherent cells were harvested and the purity of macrophages was determined using flow cytometry following staining with PECy5-conjugated anti-F4/80 Ab (BM8, eBioscience, San Diego, CA, USA). The purified macrophages (purity o95%) were cultured for 24 h. The next day, the cultured macrophages were stimulated with 50 mg/mL of oxLDL (Beijing Union-Biology Co., Ltd., Beijing, China) in the absence or presence of the ERK-specific inhibitor PD98059 (S1177, Selleck Chemicals, Houston, TX, USA) or the p38-specific inhibitor SB203580 (S1076, Selleck Chemicals, Houston, TX, USA) for the indicated times.
PCR and real-time PCR
To identify the genotype of the Pdcd4 2/2 mice, template genomic DNA was extracted from a small piece of tail from mice at age 8 weeks. PCR were performed using the following primers: Pdcd4-WT: sense: 59-AGCCATTTCAGCCTTGGTGC-39, antisense: 59-AATCTGTGTCTATGGTGAGGGTGG-39 (398-bp product length); Pdcd4-KO: sense: 59-GTTTGGAGGGAGG AAATGGAAG-39, anti-sense: 59-AATCTGTGTCTATGGTG AGGGTGG-39 (485-bp product length).
To measure cytokine expression, total RNA was isolated from the aortic arch with atherosclerotic plaques or cultured macrophages and then reverse transcribed into cDNA. Realtime PCR was performed using UltraSYBR Mixture (CW0956; CWBIO, Beijing, China) and specific primer pairs. The sequences of the sense and antisense primers were as follows: IL-10, sense: 59-GCCAGAGCCACATGCTCCTA-39, antisense: 59-GATAAGGCTTGGCAACCCAAGTAA-39; IL-6, sense: 59-CTGCAAGAGACTTCCATCCAG-39, antisense: 59-AGTG GTATAGACAGGTCTGTTGG-39; b-actin, sense: 59-CATCC GTAAAGACCTCTATGCCAAC-39, antisense: 59-ATGGAGC CACCGATCCACA-39. The relative expression data for the real-time quantitative PCR data were presented using the DDCt model. Using the 2DDCt method, our data are reported as the fold change in experimental group normalized to an endogenous reference gene (b-actin) and relative to the control group.
To assess the IL-10 RNA stability, WT and Pdcd4 2/2 peritoneal macrophages were treated with actinomycin D (10 mg/ mL) for various times (0 min, 20 min, 40 min) and the IL-10 mRNA levels were analyzed by real-time PCR and normalized to 18S. To determine the effect of mitogen-activated protein kinase inhibitors on mRNA decay, the macrophages were treated with an inhibitor of ERK (SB203580) or of p38 (PD98059), each at 20 mM, and mRNA expression was assayed as described above.
Western blot
The proteins (50 mg) were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA), which were blocked with 2% bovine serum albumin (BSA) in Tris-buffered saline 1 0.1% Tween-20 (TBST) for 1 h, then incubated overnight at 4 uC with rabbit anti-mouse antibodies against IL-10, p-JNK, JNK, p-ERK, ERK, p-p38, p38, STAT3, p-STAT3, SCOS3 (all at 1:1000; Cell Signaling Technology, Danvers, MA, USA) or rat anti-mouse b-actin (sc-1616-R, 1:2000; Santa Cruz Biotechnology), then incubated with HRP-conjugated goat anti-rabbit or HRP-conjugated anti-rat IgG for 1 h at RT. After washing three times, the signals were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL, USA) and semi-quantified with Quantity One v4.62 software.
ELISA
The supernatant was collected from cultured macrophages after stimulation with oxLDL for 6 h, 12 h, 24 h, and 48 h. The cytokines were quantified using mouse IL-10, IL-6, TNFa, TGF-b, and IL-17 ELISA kits (eBioscience) according to the manufacturer's instructions.
Flow cytometry Splenocytes isolated from Pdcd4
Apoe 2/2 and Pdcd4
Apoe 2/2 mice fed with a high fat diet for 8 weeks were stimulated with functional grade purified anti-mouse CD3e Ab (145-2C11; eBioscience) for 3 days. The supernatant was collected and used for the measurement of IL-2, IL-4, IL-6, IFN-c, TNF-a, IL-17, and IL-10 by BD Cytometric Bead Array (CBA) Mouse Th1/Th2/ Th17 Cytokine Kit (560485; BD Biosciences) according to the manufacturer's instructions. At least 2100 gated beads were acquired and analyzed with a Cytomics FC500 (Beckman Coulter, Brea, CA, USA).
In vivo application of exogenous IL-17 and neutralizing anti-IL-10 antibody Male Pdcd4 1/1 Apoe 2/2 mice (n 5 8) and male Pdcd4
Apoe 2/2 mice (n 5 16) were fed a high fat diet from 8 weeks of age. Four weeks later, the Pdcd4
Apoe 2/2 mice were divided into four groups (n 5 4 for each group) and subjected to the following treatments: intraperitoneal injection of exogenous 0.02% recombinant IL-17A in normal saline (2 mg/mouse/ time, PMC0175, Invitrogen, Carlsbad, CA, USA) or normal saline containing 0.02% albumin as control twice a week for 5 weeks; intraperitoneal injection with neutralizing anti-IL-10 antibody (250 mg/mouse/time, MAB417, rat IgG2A; R&D Systems, Minneapolis, MN, USA) or the isotype Ab (rat IgG2A, MAB006; R&D Systems) as a control once a week for 5 weeks. The control Pdcd4
Apoe 2/2 mice were divided into two groups (n 5 4 for each group) and given normal saline or isotype Ab, respectively. The levels of IL-17 and IL-10 in the sera of the mice after treatment with recombinant IL-17A or the neutralizing anti-IL-10 antibody were measured using an ELISA kit (eBioscience) according to the manufacturer's instructions.
RNA-binding protein immunoprecipitation (RIP)
Peritoneal macrophages from the C57BL/6 mice were collected, cultured, and stimulated with oxLDL for 24 h. The cells (1 3 10 7 ) were lysed by RIP lysis buffer from the RIP kit (17-701; Millipore Corporation, Billerica, MA, USA). Approximately 10% of the supernatant (cytoplasmic fraction) was saved as the input sample, and the remainder was used for IP overnight at 4 uC, using rabbit anti-mouse Pdcd4 Ab or rabbit anti-mouse IgG (negative control) or rabbit anti-mouse SNRNP70 Ab (positive control) magnetic bead complexes to obtain a RNA-protein-magnetic bead complex. The proteinmagnetic beads were removed digesting by proteinase K buffer. Then, the RNAs bound to the Pdcd4, IgG, or SNRNP70 were purified and reverse transcribed into cDNA. IL-10 expression in RNA bound to the Pdcd4 or the negative control IgG was measured using real-time PCR with IL-10-specific primers as described above, while U1 snRNA expression in the RNA bound to the positive control SNRNP70 was measured using the U1 snRNA-specific primers, sense: 59-GGGAGATACCA TGATCACGAAG GT-39, anti-sense: 59-CCACAAATTATGCA GTCGAGTTTCCC-39.
Statistical analysis
All analyses were performed using the SPSS 11.0 program (SPSS, Chicago, IL, USA). One-way analysis of variance (ANOVA) and unpaired Student's t-tests were used to compare the data for multi-group and between-group differences, respectively. The data are shown as the means 6 SEM. A probability value ,0.05 was considered statistically significant.
RESULTS
Pdcd4 deficiency increased the expression of IL-10 in macrophages and decreased the expression of IL-17 in T cells in vitro
Macrophages and T cells are major components of atherosclerotic plaques, and the cytokines secreted by these cells play a critical role in the development of atherosclerosis. To explore the possible role of Pdcd4 in atherosclerosis, we first investigated the impact of Pdcd4 on the secretion of cytokines by macrophages in vitro. Primary peritoneal macrophages from Pdcd4 2/2 mice and their littermate WT C57BL/6 animals were stimulated by the atherosclerosis-associated stimulant, ox-LDL, for various times, and the cytokine expression was determined using real-time PCR and ELISA. As shown in Figure 1 , the expression of IL-10 was persistently elevated in the oxLDLstimulated Pdcd4 2/2 macrophages at both the mRNA level ( Figure 1a ) and the protein level (Figure 1b) , and this stimulation occurred for a longer time than for the WT macrophages. Apoe 2/2 mice were stimulated with oxLDL (50 mg/mL) for the indicated time periods. The mRNA levels and concentrations of IL-10 (e, f) and IL-6 (g, h) in the supernatants were assessed by real-time PCR and ELISA, respectively. The data are shown as the means 6 SEM. *P , 0.05; **P , 0.01; ***P , 0.001. The data are derived from four mice per group. (Figure 1c) . Meanwhile, the expression of IL-6 at protein level was also not different between the two groups following long-term stimulation with oxLDL. However, the expression of IL-6 in the Pdcd4 2/2 macrophages increased at early stage (12 h) (Figure 1d ). In addition, the Pdcd4 deficiency had no obvious effect on the levels of TNF-a (Supplementary Figure 1a) and TGF-b (Supplementary Figure 1b) . To further clarify the effect of Pdcd4 deficiency on IL-10 and IL-6 secreted by the macrophages in hyperlipidemic environment, Pdcd4 2/2 Apoe 2/2 mice were generated by crossing Pdcd4 2/2 with Apoe 2/2 mice and the genotype with respect to Pdcd4 was identified (Supplementary Figure 2) . We measured the expression of IL-10 and IL-6 in oxLDL-treated macrophages from the Pdcd4 (Figure 1g and 1h) . This result indicates that macrophages lacking Pdcd4 produce more IL-10 under chronic stimulation by oxLDL in vitro.
To explore the effect of Pdcd4 deficiency on the secretion of cytokines by T cells in a hyperlipidemic environment, after feeding the mice a high fat diet for 8 weeks, the splenocytes from Pdcd4 1/1 Apoe 2/2 and Pdcd4 2/2 Apoe 2/2 mice were stimulated with anti-CD3 monoclonal antibody for 3 days. The cytokines in the culture supernatants were detected using BD CBA (Figure 2a) . As shown in Figure 2b High levels of IL-10 and low levels of IL-17 were detected in the atherosclerotic lesions of Pdcd4 2/2 Apoe 2/2 mice To determine whether Pdcd4 deficiency also upregulates the expression of IL-10 in plaques in hyperlipidemic mice, Pdcd4 1/1 Apoe 2/2 and Pdcd4 2/2 Apoe 2/2 mice were fed a high fat diet for 8 weeks to induce atherosclerotic lesions. The aortic arch with atherosclerotic plaques was isolated, and the expression of IL-10 was measured using real-time PCR and Western blot. As shown in Figure 3 , the expression of IL-10 was markedly increased in Pdcd4 2/2 Apoe 2/2 mice compared with Pdcd4 1/1 Apoe 2/2 mice at both the protein level (Figure 3a ) and the mRNA level (Figure 3b) . Further, frozen sections were prepared from the aortic root with its atherosclerotic plaques, and the IL-10 and CD68 proteins were co-localized on the same sections using dual IF staining. The results showed that IL-10 was co-expressed with CD68 in the same cells (Figure 3c ). These results indicate that the expression of IL-10 in macrophages from atherosclerotic plaques increased in Pdcd4-deficient mice.
To determine whether the changes in IL-17 associated with Pdcd4 deficiency also occur in the aortic lesions, additional sections of the aortic root on separate slides were used to evaluate the expression of IL-17 by IHC and IF. The results showed that the expression of IL-17 in the aortic lesions was significantly decreased in the Pdcd4 2/2 Apoe 2/2 mice compared with the Pdcd4 1/1 Apoe 2/2 mice (Figure 4a ). Moreover, dual IF staining for IL-17 and CD4 in the same section showed that IL-17 and CD4 were co-expressed in the same cells, which demonstrated that IL-17 was expressed in the CD4 1 T cells (Figure 4b ). These results indicate that the expression of IL-17 in CD4
1 T cells decreased in the atherosclerotic lesions of Pdcd4-deficient mice. (Figure 5a, c, and e) . However, injection of the neutralizing anti-IL10 antibody significantly decreased the level of IL-10 in the serum and reversed the protective effect of Pdcd4 deficiency on the aortic lesions (Figure 5b, d, and f) . These results indicate that upregulation of IL-10 is at least partially responsible for the reduced aortic lesions observed in the Pdcd4-deficient mice.
Pdcd4 regulated IL-10 expression in ERK1/2 and p38 MAPK pathways Previous studies have reported that LPS stimulation upregulates IL-10 expression in macrophages by downregulating Pdcd4 expression 12 . We therefore measured Pdcd4 expression in C57BL/6 macrophages stimulated with oxLDL. The results showed that the expression of Pdcd4 was reduced at 24 h after stimulation, which is consistent with the results for macrophages treated with LPS as described in a previous report 12 , while the levels were elevated at 48 h after oxLDL stimulation (Figure 6a ). These data suggest that long-term stimulation with this toxic lipid increased the expression of Pdcd4, which is consistent with the data from the plaques. Pdcd4 has been recognized as a suppressor of both gene transcription and translation via binding to eIF4A, which interacts with mRNAs containing 59-untranslated regions (UTRs) 5 , and direct binding to the target genes, respectively 3 . Because the IL-10 mRNA contains 59-UTRs, it has been speculated that IL-10 may be inhibited by the Pdcd4-eIF4A complex. We therefore explored the mechanism by which Pdcd4 regulates IL-10 expression using the RIP assay. As shown in Figure 6b , the positive control (U1 snRNA from anti-SNRNP70) was detected, but the IL-10 amplification product was not detected by the anti-Pdcd4 Ab, indicating that , we examined these pathways by Western blotting. The results showed that Pdcd4 deficiency markedly increased the phosphorylation of ERK1/2 and P38 but did not affect the phosphorylation of JNK (Figure 6c ), STAT3 and SOCS3 (Supplementary Figure 5) . Furthermore, inhibition of ERK1/2 and P38 activation using their specific inhibitors (PD98059 and SB203580, Figure 6d ) reversed the difference in the IL-10 levels induced by Pdcd4 deficiency, respectively (Figure 6e) . To exclude an effect of Pdcd4 on the stability of IL-10 mRNA, we also measured the changes in the levels of IL-10 mRNA after treatment of actinomycin D, an inhibitor of de novo transcription. As shown in Supplementary Figure 6 , the level of IL-10 mRNA in all groups (the presence or absence of Pdcd4 or the presence or absence of ERK and P38 inhibitors, PD98095 and SB203580) decreased to less 50% within 40 min of treatment with actinomycin D, suggesting that Pdcd4 had no effect on the stability of the IL-10 mRNA (Supplementary Figure 6) . Taken together, these results indicate that Pdcd4 inhibits the transcription of IL-10 through the ERK1/2 and P38 MAPK pathways in macrophages.
DISCUSSION
In the present study, we demonstrated that a deficiency in Pdcd4 attenuates the development of atherosclerotic lesions in hyperlipidemic mice by upregulating the antiinflammatory cytokine IL-10. Our finding suggests that Pdcd4 is a potential novel target for an anti-atherosclerosic therapeutic agent.
The accumulating evidence from both murine models and human primary tumors indicates that Pdcd4 is an oncogene suppressor that inhibits the proliferation of multiple types of tumor cells and suppresses their malignant phenotype [6] [7] [8] [9] [10] [11] 38 . In the present study, we provide the first evidence that Pdcd4 deficiency suppresses the formation of atherosclerotic lesions. These data are consistent with previous studies of autoimmune encephalomyelitis, LPS-induced shock, type 1 diabetes, and diet-induced obesity [11] [12] [13] [14] . In addition, downregulation of Pdcd4 by miR-21 was shown to protect cardiac cells against ischemia/reperfusion or reactive oxygen species (ROS)-induced injury 39, 40 . Taken together, these results indicate that Pdcd4 plays an essential role in promoting inflammation.
Although data from several disease models indicate that a deficiency in Pdcd4 attenuates inflammatory diseases, the underlying mechanisms for these effects are unclear. Previous studies have reported that Pdcd4 inhibits the expression of the anti-inflammatory cytokine IL-10 and that KO or knockdown of Pdcd4 significantly upregulates IL-10 production 11, 12, 35 . Consistent with these previous reports, in the present study, we observed that Pdcd4-deficient macrophages stimulated with oxLDL produce a higher level of IL-10 than WT cells, mice (Figure 5d and 5f). These results suggest that other factors may also be involved in the Pdcd4-mediated regulation of atherosclerosis. In our previous studies, we have found that a deficiency in Pdcd4 attenuates adipocyte foam cell formation 14 and more recent data show that the deficiency in Pdcd4 also attenuated macrophage foam cell formation (data not shown). These data suggest that the Pdcd4 deficiency-associated attenuated formation of macrophage foam cells may contribute to the decrease in lesions. However, more experiments are needed to address this issue in the future.
Although a previous report indicated that Pdcd4 regulates IL-10 expression at the translational level 12 , by using the RIP assay, we found that Pdcd4 cannot bind directly or indirectly to the IL-10 mRNA, suggesting that Pdcd4 does not inhibit IL-10 translation. Consistent with two recent reports 35, 36 , we observed that the Pdcd4-deficient macrophages from both Pdcd4 2/2 mice and Pdcd4 2/2 Apoe 2/2 mice expressed high levels of IL-10 mRNA, suggesting that Pdcd4 regulates the expression of IL-10 at the transcriptional level. Our further results indicated that the increased IL-10 mRNA transcription observed in macrophages lacking Pdcd4 was mediated by activation of ERK1/2 and p38 rather than through the JNK MAPK, STAT3 or SOCS3 pathways. Furthermore, we have excluded an effect of Pdcd4 on the stability of IL-10 mRNA using inhibitors of de novo transcription (actinomycin D) in the presence or absence of Pdcd4 and in the presence or absence of ERK1/2 and p38 inhibitors. More recent research has shown that Pdcd4 can inhibit the transcription of IL-10 through the Twist2/c-Maf pathway. Under normal condition, Pdcd4 forms a complex with the transcription factor Twist2 and then blocks the binding of Twist2 to the c-Maf promoter. The degradation of Pdcd4 induced by LPS stimulation leads to the disruption of this complex, allowing Twist2 to bind to the c-Maf promoter, which induces transcription of IL-10. It has been reported that the phosphorylation of c-Maf is essential for its transcriptional and biological properties and that p38/ERK MAP kinase can phosphorylate c-Maf, which regulates the activity of c-Maf 41, 42 . These results suggest that Pdcd4 may inhibit the expression of IL-10 by inhibiting the p38/ERK-c-Maf pathway. However, more experiments are needed to address this issue. 2/2 mice were collected, cultured in vitro, stimulated with oxLDL (50 mg/mL) and blocked with ERK1/2 inhibitor (PD98059) or p38 inhibitor (SB203580) for 12 h. The expression of p-ERK1/2 and p-P38 after blocking with the inhibitors was detected by Western blotting and semi-quantified. The number of replicates in experimental groups compared with control was indicated. (e) The concentrations of IL-10 in the culture supernatants were measured using ELISA. The pooled data 6 SEM are shown. *P , 0.05. The data are derived from three separate experiments.
PDCD4 affects atherosclerosis by regulating IL-10 Y Jiang et al
Recently, studies have shown that IL-17, a major effector molecule of Th17 cells, is involved in atherosclerosis. However, its role is unclear, given conflicting results that have shown both protective and pathogenic effects 43, 44 . In the present study, we found that Pdcd4 deficiency led to decreased production of IL-17 by T cells in vitro and a low level of IL-17 expression in CD4
1 T cell of atherosclerotic lesion in Pdcd4 2/2 Apoe 2/2 mice. However, supplementation with exogenous IL-17 did not reverse the attenuated atherosclerosis. A similar phenomenon was also observed in diabetic models in which the change in IL-17 in the splenocytes from Pdcd4 2/2 NOD mice was not consistent with the attenuated diabetes after Pdcd4 deficiency 13 . These results suggest that, although Pdcd4 deficiency can change IL-17 expression, this change had no causal relationship with the attenuation of atherosclerotic plaques observed in Pdcd4 deficiency. Blocking IL-10 with a neutralizing antibody significantly reversed the Pdcd4 deficiency-induced decrease in the atherosclerotic lesions but supplementation with exogenous IL-17 did not, despite the fact that the level of IL-17 was markedly increased following the IL-17 treatment ( Figure 5 ). These results suggest that effect of Pdcd4 on IL-17 may be indirect. The reduction of IL-17 in the plaques of the Pdcd4 2/2 Apoe 2/2 mice may be due to the improved inflammatory environment induced by the high level of IL-10.
Taken together, these results indicate that Pdcd4 negatively regulates the expression of IL-10 in an ERK1/2-and p38-dependent manner and thereby promotes atherosclerosis.
